PRECLINICAL
PHASE 1
PHASE 2
PHASE 3

RSLV-132

Sjögren’s Syndrome
Long Covid
Systemic Lupus Erythematosus

RSLV-621 – Interferon Antagonist

Systemic Lupus Erythematosus

Second Generation Nuclease Platform

Autoimmune NETosis - Vasculitis

RSLV-132

RSLV-132, our lead product candidate, is a novel compound that eliminates inflammatory nucleic acids, which are known to accumulate in lupus and Sjögren’s syndrome patients and cause chronic inflammation.

LEARN MORE

RSLV-621

RSLV-621 is an Fc-fusion protein consisting of the IFNAR1 and IFNAR2 subunits of the type I interferon receptor.  It is a potent (sub-nanomolar) inhibitor of type I interferons.  The recent launch of anifrolumab has demonstrated the clinical importance of inhibiting type I interferons in SLE and has provided a regulatory roadmap for other interferon antagonists.  A phase 1 POC study in SLE patients is planned with RSLV-621 and will provide safety and tolerability data as well as the degree of interferon signature knockdown.  If the interferon signature is significantly inhibited in this study a large P2 will be embarked on.

Bi-Specific Nuclease Platform

This nuclease platform will include human Fc fusion proteins consisting of both RNase and DNase. Our preclinical asset, RSLV-133, will be tested in lupus nephritis, an autoimmune disease in which both RNA and DNA contribute to inflammation causing kidney damage.